Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home, Philip D; Pocock, Stuart J; Beck-Nielsen, Henning; Curtis, Paula S; Gomis, Ramon; Hanefeld, Markolf; Jones, Nigel P; Komajda, Michel; McMurray, John JV; RECORD Study Team; (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 373 (9681). pp. 2125-2135. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(09)60953-3

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S0140-6736(09)60953-3

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar